Search results for: “oncology”
-
Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology
•
LONDON: Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor…
-
Novartis will acquire Mariana Oncology for up to $1.75 billion
•
Novartis will acquire Mariana Oncology, a fully integrated biotechnology company and pioneer in a new era of radiopharmaceutical…
-
CG Oncology goes public with $380 million IPO, Malin’s stake rises in value
•
LONDON, UK: CG Oncology, a biotechnology company focused on cancer immunotherapy, has launched its initial public offering (IPO)…
-
AbbVie to buy ImmunoGen for $10.1 billion, boosting its oncology portfolio
•
AbbVie Inc. (NYSE: ABBV) announced today that it has agreed to acquire ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology…
-
Dimerix appoints former Race Oncology CMO Dr David Fuller
•
MELBOURNE, AUSTRALIA: Dimerix Limited (Dimerix), a biotechnology company developing novel treatments for kidney diseases, has announced the appointment…
-
Quest Diagnostics acquires oncology company Haystack for $450 million
•
Quest Diagnostics, a provider of diagnostic information services based in Seacaucus, New Jersey, has acquired Haystack Oncology, an…
-
Race Oncology appoints Damian Clarke as MD & CEO
•
SYDNEY, AUSTRALIA: Race Oncology Limited announced that Mr Damian Clarke-Bruce has been appointed Managing Director and Chief Executive…
-
GSK agrees to acquire Sierra Oncology for $1.9bn
•
LONDON, UK: GlaxoSmithKline plc (LSE: GSK) and Sierra Oncology Inc (Nasdaq: SRRA) have entered into an agreement under…
-
Celyad Oncology sells 28.8% shares to Fortress Group for $32.5mn
•
BRUSSELS, BELGIUM: Celyad Oncology SA has entered into a subscription agreement with an affiliate of Fortress Investment Group…
-
Pyxis Oncology prices Nasdaq IPO at $16/share
•
LONDON, UK: Arix Bioscience plc, a global venture capital company focused on investing in and building breakthrough biotech…
-
Celyad Oncology signs $40 million equity purchase agreement with Lincoln Park Capital
•
BRUSSELS: Celyad Oncology SA has entered into a committed equity purchase agreement for up to $40 million with…
-
Redx Pharma appoints leading oncology drug developer, Dr Jane Robertson, as Chief Medical Officer
•
ALDERLEY PARK: Redx Pharma plc has appointed Dr Jane Robertson as Chief Medical Officer, a news release noted.…
Stay Informed with the Latest News and Updates
- Contact Us
- London Stock Exchange
- Singapore Exchange
- Canadian Exchange
- Australian Exchange
- Oslo Bourse
- PSX
- Ratings
- Euronext
- MENA
- Nasdaq Nordic
- Wire
- Business & Finance
- Gadget Reviews
- About Us: A Comprehensive Financial News Database
All news and articles on NewsnReleases are based on press releases, corporate announcements and analysts’ reports issued to London Stock Exchange (LSE), Euronext, Singapore Exchange (SGX), Japan Stock Exchange (JPX), Dubai Financial Market (DFM), Saudi Stock Exchange (Tadawul), Qatar Stock Exchange (QSE), BSEIndia, Australia Stock Exchange etc.